103 related articles for article (PubMed ID: 2592776)
1. Tumor growth in vivo selects for resistance to tumor necrosis factor.
Lattime EC; Stutman O
J Immunol; 1989 Dec; 143(12):4317-23. PubMed ID: 2592776
[TBL] [Abstract][Full Text] [Related]
2. Evidence of a role for TNF-alpha in cytolysis by CD4+, class II MHC-restricted cytotoxic T cells.
Tite JP
Immunology; 1990 Oct; 71(2):208-12. PubMed ID: 2228021
[TBL] [Abstract][Full Text] [Related]
3. Expression of the tumor necrosis factor gene in tumor cells correlates with reduced tumorigenicity and reduced invasiveness in vivo.
Vanhaesebroeck B; Mareel M; Van Roy F; Grooten J; Fiers W
Cancer Res; 1991 Apr; 51(8):2229-38. PubMed ID: 2009541
[TBL] [Abstract][Full Text] [Related]
4. In vitro selection of a cell line for resistance to lysis by tumor necrosis factor-alpha selects for reduced tumorigenicity.
Patek PQ; Lin Y
J Immunol; 1991 May; 146(10):3457-61. PubMed ID: 2026874
[TBL] [Abstract][Full Text] [Related]
5. Effect of ultraviolet irradiation on MCA102 tumor cell immunogenicity and sensitivity to tumor necrosis factor.
Gorelik E; Begoviĉ M; Duty L; Herberman RB
Cancer Res; 1991 Mar; 51(5):1521-8. PubMed ID: 1997193
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro.
Tomazic VJ; Farha M; Loftus A; Elias EG
J Immunol; 1988 Jun; 140(11):4056-61. PubMed ID: 3372997
[TBL] [Abstract][Full Text] [Related]
7. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
Peters PM; Ortaldo JR; Shalaby MR; Svedersky LP; Nedwin GE; Bringman TS; Hass PE; Aggarwal BB; Herberman RB; Goeddel DV
J Immunol; 1986 Oct; 137(8):2592-8. PubMed ID: 3760569
[TBL] [Abstract][Full Text] [Related]
8. In vivo or in vitro selection for resistance to natural cytotoxic cell lysis selects for variants with increased tumorigenicity.
Patek PQ; Lin Y; Collins JL; Cohn M
J Immunol; 1986 Jan; 136(2):741-5. PubMed ID: 3941271
[TBL] [Abstract][Full Text] [Related]
9. Resistance of primary CD8+ cytotoxic T lymphocytes to lysis by cytotoxic granules from cloned T cell lines.
Nagler-Anderson C; Verret CR; Firmenich AA; Berne M; Eisen HN
J Immunol; 1988 Nov; 141(10):3299-305. PubMed ID: 2972770
[TBL] [Abstract][Full Text] [Related]
10. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
11. Two discrete types of tumor necrosis factor-resistant cells derived from the same cell line.
Vanhaesebroeck B; Van Bladel S; Lenaerts A; Suffys P; Beyaert R; Lucas R; Van Roy F; Fiers W
Cancer Res; 1991 May; 51(9):2469-77. PubMed ID: 1849793
[TBL] [Abstract][Full Text] [Related]
12. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
Gorelik E; Gunji Y; Herberman RB
J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
[TBL] [Abstract][Full Text] [Related]
13. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
[TBL] [Abstract][Full Text] [Related]
14. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
[TBL] [Abstract][Full Text] [Related]
15. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
16. H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma.
Nishimura MI; Stroynowski I; Hood L; Ostrand-Rosenberg S
J Immunol; 1988 Dec; 141(12):4403-9. PubMed ID: 3264312
[TBL] [Abstract][Full Text] [Related]
17. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
Takeda K; Smyth MJ; Cretney E; Hayakawa Y; Yamaguchi N; Yagita H; Okumura K
Cell Immunol; 2001 Dec; 214(2):194-200. PubMed ID: 12088418
[TBL] [Abstract][Full Text] [Related]
18. Natural cytotoxic cells and tumor necrosis factor activate similar lytic mechanisms.
Patek PQ; Lin Y; Collins JL
J Immunol; 1987 Mar; 138(5):1641-6. PubMed ID: 3805728
[TBL] [Abstract][Full Text] [Related]
19. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
20. Methylcholanthrene-induced mouse sarcomas express individually distinct major histocompatibility complex class I-associated peptides recognized by specific CD8+ T-cell lines.
Kono K; Petersson M; Ciupitu AM; Wen T; Klein G; Kiessling R
Cancer Res; 1995 Dec; 55(23):5648-55. PubMed ID: 7585649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
